Head to Head Survey: Genelux (GNLX) & Its Competitors

Genelux (NASDAQ:GNLX) is one of 846 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Genelux to similar businesses based on the strength of its earnings, risk, dividends, analyst recommendations, institutional ownership, profitability and valuation.

Profitability

This table compares Genelux and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Genelux Competitors	-12,283.59%	-195.39%	-30.85%

Insider & Institutional Ownership

37.3% of Genelux shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Genelux has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Genelux’s competitors have a beta of 1.15, suggesting that their average stock price is 15% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Genelux and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	2	1	2.75
Genelux Competitors	9904	15278	45630	1595	2.54

Genelux presently has a consensus price target of $20.00, suggesting a potential upside of 963.83%. As a group, “Biotechnology” companies have a potential upside of 120.28%. Given Genelux’s stronger consensus rating and higher possible upside, research analysts plainly believe Genelux is more favorable than its competitors.

Valuation and Earnings

This table compares Genelux and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Genelux	$10,000.00	-$32.15 million	-2.19
Genelux Competitors	$704.22 million	$10.96 million	-15.00

Genelux’s competitors have higher revenue and earnings than Genelux. Genelux is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Genelux competitors beat Genelux on 8 of the 13 factors compared.

Genelux Company Profile

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer. Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.